Clearpoint Neuro, Inc. — Q1 2014 Form 10-Q Summary
Issuer identification: The supplied filing names the registrant as MRI Interventions, Inc., not Clearpoint Neuro, Inc. This summary reflects the filing text provided. The unaudited quarter ended March 31, 2014; comparisons are with Q1 2013 unless otherwise stated.
Business context
MRI Interventions develops and commercializes technology for minimally invasive procedures guided by intra-procedural MRI. Its ClearPoint brain-procedure system had U.S. FDA 510(k) clearance and EU CE marking. ClearTrace, intended for MRI-guided cardiac procedures, remained in development and was not cleared for commercial use.
Financial performance and position
| Metric | Q1 2014 / March 31, 2014 | Comparable period / prior year-end |
|---|---|---|
| Total revenue | $823,000 | $1.264 million, Q1 2013; down 35% |
| Product revenue | $713,000 | $460,000, Q1 2013; up 55% |
| Development service revenue | $99,000 | $154,000, Q1 2013; down 36% |
| Net income (loss) | $2.630 million; $0.04 per basic and diluted share | $(824,000); $(0.02) per share, Q1 2013 |
| Cash and cash equivalents | $5.801 million | $3.516 million, December 31, 2013 |
| Current assets / current liabilities | $7.989 million / $5.115 million | Working capital: $2.874 million |
| Total liabilities | $13.185 million | $14.707 million, December 31, 2013 |
| Accumulated deficit | $70.122 million | $72.753 million at December 31, 2013 |
| Cash used in operations | $1.359 million | $2.243 million, Q1 2013 |
Product revenue growth included disposable product sales of $565,000, up 63%, driven primarily by more ClearPoint procedures and contract catheter sales. Reusable-product revenue was about $92,000, compared with $113,000 a year earlier. Q1 2014 product gross profit was approximately $363,000, or 51% of product revenue, based on reported product revenue and cost of product revenue.
Reported operating income was $2.192 million, versus an operating loss of $1.367 million in Q1 2013. The 2014 result included a $4.339 million gain from selling intellectual property; excluding that gain, operations remained loss-making. The company also recognized a $484,000 gain from a change in the fair value of warrant liabilities. These non-cash or transaction-related gains materially affected reported earnings.
Cash increased by $2.285 million during the quarter, principally because of $3.646 million in financing cash flow, including the March debt offering and option exercises. Investing cash outflow was $2,000. Operating cash use remained significant despite reported net income, which included the intellectual-property gain.
Material changes and unusual items
- In March, Boston Scientific purchased specified MRI-safety intellectual property for $4.339 million, satisfied by cancellation of related-party convertible notes of the same amount that were scheduled to mature in 2014. The transaction produced the reported gain and released the related liens.
- Under related amendments, MRI Interventions gave up potential future milestone payments and royalties under its Boston Scientific development and license agreements. It received an exclusive, royalty-free license to the transferred intellectual property for fields outside neuromodulation and cardiac implantable medical leads. The filing states the transaction did not affect ClearPoint commercialization or ClearTrace development.
- The company raised $3.725 million gross, or $3.503 million net, through 12% second-priority secured non-convertible notes due in 2019, together with warrants for up to 1,117,500 shares. Non-employee directors invested $1.1 million. The notes are secured junior to the Brainlab senior secured note.
- A February 2014 Siemens agreement replaced the prior development arrangement. MRI Interventions will develop a commercial version of Siemens’ research software platform, with Siemens cooperation; commercialization remains subject to regulatory clearance or approval.
- Basic and diluted weighted-average shares were 58.7 million and 61.2 million, respectively, versus 54.9 million basic and diluted shares in Q1 2013. Common shares outstanding at March 31 were 58.9 million.
Outlook, liquidity, risks and contingencies
Management expected cash at March 31, 2014, together with cash expected from product sales, to fund anticipated requirements through at least March 2015. It expected ClearPoint revenue to increase during the remainder of 2014, citing sales and clinical-support hires made in 2013, while anticipating continued losses at least through year-end. This outlook depends on sales growth and is not a guarantee; the company stated that additional financing might be needed and could be dilutive or unavailable on acceptable terms. Possible spending reductions include deferring development, hiring, patent and other planned expenditures.
- Key risks include limited market acceptance of ClearPoint, the need to expand sales and clinical support, reimbursement uncertainty, competition, dependence on single-source suppliers and limited manufacturing capacity.
- ClearTrace requires further development and regulatory clearance or approval; the filing highlights uncertainty around development costs, clinical work and regulatory timing.
- Summer Street arbitration was pending, with a hearing scheduled for July 2014. The claimant sought $480,000 in commissions and warrants for 460,338 shares; the company asserted counterclaims. No liability was recorded because management assessed a material adverse outcome as remote, but said the outcome could not be reasonably estimated.
- Management concluded disclosure controls and procedures were effective as of March 31, 2014 and reported no material change in internal control over financial reporting during the quarter.
Most important facts for investors to verify
- Confirm the issuer identity: the filing text is for MRI Interventions, Inc., despite the request naming Clearpoint Neuro, Inc.
- Assess the quality of Q1 earnings: the $2.630 million net income depended heavily on a $4.339 million intellectual-property gain and a $484,000 warrant remeasurement gain.
- Review liquidity and financing assumptions, including management’s March 2015 runway estimate, continuing operating cash use and the possibility of additional capital needs.
- Examine the 12% secured notes, collateral priority, warrant dilution and the remaining Brainlab senior secured debt terms and maturities.
- Track the commercial uptake of ClearPoint, recurring disposable sales, and ClearTrace development and regulatory progress.
- Monitor the Summer Street arbitration and the loss of potential Boston Scientific milestone and royalty revenues.